Jose Gamez-Godoy
Pediatric Endocrinology · Edinburg, TXNPI 1992952758
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $155,519 of the $207,451 with a category attached, or 75.0%. 23 manufacturers reported payments, led by Novo Nordisk at 46.7% of the total. 2025 is the largest year on record at $119,884, more than ten times the $359 reported in 2019. Among pediatric endocrinology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $871.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$97K
- Neurocrine Biosciences, Inc.$37K
- Ascendis Pharma Endocrinology Inc$27K
- Rhythm Pharmaceuticals, Inc.$23K
- Sanofi-aventis U.S. LLC$13K
- Arbor Pharmaceuticals, Inc.$4K
- plus $6K from 17 others
Across 13 payments — averaging $1611.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20K
- AbbVie$869
What the payments were for
- Consulting fees$20,83510%
- Speaking & faculty fees$155,51975%
- Travel & lodging$23,81311%
- Food & beverage$7,1433%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $96,874 |
| Neurocrine Biosciences, Inc. | 38 | $37,190 |
| Ascendis Pharma Endocrinology Inc | 30 | $27,279 |
| Rhythm Pharmaceuticals, Inc. | 29 | $22,828 |
| Sanofi-aventis U.S. LLC | 10 | $13,158 |
| Arbor Pharmaceuticals, Inc. | 5 | $3,896 |
| Soleno Therapeutics, Inc. | 5 | $3,247 |
| Azurity Pharmaceuticals, Inc. | 4 | $1,270 |
| Mannkind Corporation | 2 | $365 |
| Biomarin Pharmaceutical Inc. | 3 | $270 |
| Dexcom, Inc. | 5 | $223 |
| AstraZeneca | 2 | $215 |
| Ultragenyx Pharmaceutical Inc. | 3 | $197 |
| Pfizer | 1 | $116 |
| Eton Pharmaceuticals, Inc. | 3 | $97 |
| Insulet Corporation | 3 | $63 |
| AbbVie | 3 | $62 |
| Tolmar, Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 2 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sogroya$94,919
- CRENESSITY$35,437
- SKYTROFA$27,044
- Imcivree$15,176
- TZIELD$13,130
- Triptodur$4,996
- VYKAT XR$3,230
- Norditropin$950
- AFREZZA$365
- VOXZOGO 1.2mg$131
- LOKELMA$125
- Macrilen$123
- DEXCOM G6 TRANSMITTER$121
- GENOTROPIN$116
- Rivfloza$108
- CRYSVITA$106
How this compares
$207,451 in reported general payments places this provider in the 95th percentile of 120 pediatric endocrinology providers in Texas.
Other pediatric endocrinology in Edinburg
- Ranjana Regunatha SarmaEdinburg$2K
- Horacio Velasquez MunozEdinburg$818
- Virginia AraizaHouston$151K
- Daniel DesalvoHouston$133K
- Amy BurtonPlano$130K
- Susan NunezAustin$91K
- Hector GranadosEl Paso$73K
- Donnie WilsonFort Worth$58K
- Paul ThorntonFort Worth$52K
- Jane LynchSan Antonio$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.